Literature DB >> 22607855

Multiple biomarkers at admission are associated with angiographic, electrocardiographic, and imaging cardiovascular mechanistic markers of outcomes in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction.

Peter Damman1, Wichert J Kuijt, Pier Woudstra, Joost D E Haeck, Karel T Koch, Youlan L Gu, Jan P van Straalen, Johan Fischer, Jan G P Tijssen, Mitchell W Krucoff, Robbert J de Winter.   

Abstract

BACKGROUND: The multimarker risk score, based on estimated glomerular filtration rate, glucose, and N-terminal probrain natriuretic peptide (NT-proBNP), has been shown to predict mortality in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). In this study, we investigated the relation between the multimarker risk score and cardiovascular mechanistic markers of outcomes in STEMI patients undergoing PPCI.
METHODS: Complete biomarkers were available in 197 patients with STEMI. Angiographic Thrombolysis In Myocardial Infarction flow grade and myocardial blush grade at the end of the PPCI, electrocardiographic ST-segment resolution (STR) at the time of last contrast injection and 240 minutes after last contrast, and cardiac magnetic resonance (CMR) left ventricular ejection fraction (LVEF) and infarct size at 4 to 6 months after the index event were available.
RESULTS: In linear regression models, higher multimarker scores were associated with worse angiographic (P < .01 for both outcomes), electrocardiographic (P < .001 for the association with STR at last contrast, and P < .01 for STR at 240 minutes), and CMR outcomes (P < .01 for both).
CONCLUSIONS: The multimarker risk score is associated with angiographic, electrocardiographic, and CMR mechanistic markers of outcomes. These data support the ability of the multimarker risk score to identify patients at high risk for suboptimal reperfusion and CMR outcomes and may aid in the early triage of patients who stand to benefit most of adjuvant treatments in STEMI.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22607855     DOI: 10.1016/j.ahj.2012.01.004

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  2 in total

1.  The contemporary value of peak creatine kinase-MB after ST-segment elevation myocardial infarction above other clinical and angiographic characteristics in predicting infarct size, left ventricular ejection fraction, and mortality.

Authors:  Minke H T Hartman; Ruben N Eppinga; Pieter J J Vlaar; Chris P H Lexis; Erik Lipsic; Joost D E Haeck; Dirk J van Veldhuisen; Iwan C C van der Horst; Pim van der Harst
Journal:  Clin Cardiol       Date:  2016-12-27       Impact factor: 2.882

2.  Multiple biomarkers for the prediction of short and long-term mortality after ST-segment elevation myocardial infarction: the Amsterdam Groningen collaboration.

Authors:  Peter Damman; Marthe A Kampinga; Iwan C C van der Horst; Pier Woudstra; Maik J Grundeken; Wichert J Kuijt; Ralf E Harskamp; Maarten W N Nijsten; Felix Zijlstra; Jan G P Tijssen; Bart J G L de Smet; Robbert J de Winter
Journal:  J Thromb Thrombolysis       Date:  2013-07       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.